Incidence and Mortality of Cerebral Venous Thrombosis in a Norwegian Population.
Espen Saxhaug Kristoffersen, Charlotte Elena Harper, Kjersti Grøtta Vetvik...
https://pubmed.ncbi.nlm.nih.gov/32883194Actively Recruiting
All Genders
ID05021198
Epidemiology, Clinical and Radiological Presentation and Long-term Prognosis of Cerebral Venous Thrombosis in a Norwegian Population (NoCVT)
Led by University Hospital, Akershus · Updated on 2025-02-05
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Akershus
Lead Sponsor
O
Oslo University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying cerebral venous thrombosis (CVT) in a large Norwegian population of over 3 million people to better understand its causes, diagnosis, treatment, and long-term outcomes. The study combines data from multiple health registries, clinical databases, and newly collected clinical information to explore the disease's epidemiology and prognosis from 2014 to 2023. The study includes a retrospective review of hospital records from 13 hospitals covering all health regions in Norway, identifying patients diagnosed with CVT during this period. These data are linked with national registries to describe risk factors, clinical and radiological presentation, treatments, and short-term outcomes. Additionally, the study follows patients up to five years after CVT diagnosis to assess mortality, healthcare use, medication patterns, work status, and other long-term results. Participants diagnosed with CVT from 2019 to 2023 will also be invited for prospective follow-up, including interviews and questionnaires to evaluate quality of life, psychological health, vocational outcomes, and disease-related disability. The primary outcome measures include mortality rates at multiple time points, and secondary outcomes cover healthcare utilization, medication use, re-admissions, new diagnoses, and symptoms such as headache, seizures, and sleep problems over a five-year period.
CONDITIONS
Brief Title
The Norwegian Cerebral Venous Thrombosis Study
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Diagnosed with cerebral venous thrombosis (CVT) between 2014 and 2023 at one of the 13 participating hospitals in Norway
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 10 years retrospective data collection
Participants’ hospital records are reviewed retrospectively to collect clinical and radiological data related to cerebral venous thrombosis diagnosis.
No visits; data collected from medical records
Long-term Monitoring
Duration - Up to 5 years
Participants are observed for long-term prognosis including mortality, health care utilization, medication use, and work situation up to five years after diagnosis.
Follow-up interviews and self-reported questionnaires at multiple timepoints
Trial Site Locations
Total: 1 location
1
Akershus University Hospital
Lørenskog, Norway, 1478
Actively Recruiting
Loading map...
Research Team
E
Espen Saxhaug Kristoffersen, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here